BioSpace News Archive

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units (“RSUs”) to Kenneth D. Knight, Invitae’s new Chief Operating Officer and Karthik Suri, Invitae’s new Chief Digital Officer.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.

Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.00 per share

Asahi Kasei has established industrial manufacturing technology for hyaluronic acid nanogel* as a new pharmaceutical excipient, and is providing samples to prospective customers in order to commercialize the product.

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday, August 12, 2020

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020.

Model N, Inc., the leading provider of cloud revenue management solutions for Life Sciences and High Tech companies, announced financial results for the third quarter fiscal year 2020 ended June 30, 2020.

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medexus Pharmaceuticals Inc. (TSX-V: MDP; OTCQX: PDDPF), a commercial-stage specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market.